Conference abstractPublished 18 Jun 2018
Efficacy comparison among three Pegylated interferon alfa monotherapies based on 24 week response in HBeAg-positive CHB patients
Southwest Hospital, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
40 kD PEG IFN α-2a and 12kD PEG IFN α-2b have demonstrated effective immune control and resulted in better response in HBeAg positive CHB patients compared to nucleos(t)ide drugs (NUCs), e.g. HBeAg seroconversion and HBsAg loss. [1,2]However, efficacy of another PEG IFN α, i.e. 40kD PEG IFN α-2b, has not been reported yet. Aim This study aimed to compare efficacy among three PEG IFNα monotherapies in antiviral treatment-naïve HBeAg-positive CHB patients. Material and Methods Total 117 antiviral treatment-naïve HBeAg-positive CHB patients were enrolled. Subjects were randomly to receive 24 weeks of 40kD PEG IFN-α-2a (180 μg/week, Group A, n=41), 12kD PEG IFN α-2b (80μg/week, Group B, n=41), or 40kD PEG IFN-α-2b (180 μg/week, Group C, n=52) monotherapy. Primary endpoint was defined as satisfactory response (virological and biochemical response, plus anti-HBe seroconversion) at week 24. Secondary endpoints included ideal response (HBsAg loss) and HBsAg decline at week 24. All patients were further followed up during treatment. Results There were no significant differences in sex, age, HBV genotype and ALT level among three monotherapy groups (P>0.05). After treatment of 24 weeks, satisfactory response rate in 40kD PEG IFN-α-2b group (30.77%,16/52) was higher than Group A (17.07%, 7/41, P=0.1285) and Group B (12.20%,5/41, P=0.0634), although with no statistically significant difference (P>0.05). Ideal response rates in 40kD PEG IFN-α-2b group (17.31%,9/52) was slightly higher than Group A (7.32%,3/41, P=0.1536)and Group B (4.87%,2/41, P=0.0653) . Partial response rates as HBsAg level decline from baseline were a bit higher in 40kD PEG IFN-α-2b group compared to 40kD PEG IFN-α-2a group (P>0.05)(Table). Conclusion Compared to 40kD PEG IFN-α-2a and 12kD PEG IFN α-2b monotherapies, 40kD PEG IFN-α-2b monotherapy showed trends for better efficacy for antiviral treatment-naïve HBeAg positive patients at week 24. Meanwhile, 40kD PEG IFN-α-2b is at a much cheaper price, which exerts a better cost effects. Table Table. Response after treatment of 12 weeks HBsAg decline from baseline Group A 40kD PEG IFN-α-2a (n=41) Group B 12kD PEG IFN α-2b (n=41) Group C 40kD PEG IFN-α-2b (n=52) P 1lg-2lg HBsAg decline from baseline 7(17.1%) _ 8(15.4%) 0.8265 2lg-3lg HBsAg decline from baseline 12 (29.2%) _ 13(25.0%) 0.6452 ≥3lg HBsAg decline from baseline 18(43.9%) _ 29(55.8%) 0.2558
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Yuming Wang”